The pharmacological suppression of TG2 has been reported to decrease apoptosis in the brain and vascular smooth muscle cells [25,26] and reduce fibrosis and progression in CKD and diabetic kidney animal models [27,28]. This evidence concerns the gene TGM2 and chronic kidney disease.